Healthcare Industry News: HemoSense
News Release - November 4, 2008
Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&DSAN DIEGO, Nov. 4 -- (Healthcare Sales & Marketing Network) -- Accumetrics, Inc. announces the appointment of William H. Dippel to the position of Executive Vice President of Operations and R&D. Mr. Dippel will oversee the Operations, Research and Product Development departments at Accumetrics.
"We are excited to have Bill join our team," said Timothy Still, President and Chief Executive Officer of Accumetrics. "Bill's 33 years of operations and R&D experience in the healthcare industry will be a tremendous asset to Accumetrics."
Prior to joining Accumetrics, Mr. Dippel was Vice President of Operations at Barrx Medical, Inc. Before joining Barrx, Mr. Dippel was Executive Vice President of HemoSense, Inc., responsible for R&D, Manufacturing, Engineering, Materials, and Facilities Management. He provided strong leadership introducing lean manufacturing resulting in improvements in gross margin, and later played a key role during the acquisition of HemoSense by Inverness Medical Innovations.
Prior to that position, Mr. Dippel was Vice President of Operations for Micro Therapeutics -- eV3. Earlier in his career, Mr. Dippel was with Conceptus, Inc. as Vice President of R&D and Operations, and PercuSurge (now a division of Medtronic, Inc.) as Vice President of Operations and held senior positions with Boehringer Mannheim GmbH (now Roche Diagnostics), Ciba Corning Diagnostic Corporation and Spectrum Technology, Inc.
Mr. Dippel holds a B.S. in Mechanical Engineering from the California State Polytechnic University, Pomona, California.
Accumetrics is committed to advancing medical understanding of the platelet function and enhancing the quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow® System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix®, ReoPro®, and Integrilin®, the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.